Shares of Hims & Hers were on fire Monday because the FDA's new leader seems to be a fan of the company's business model.

Hims & Hers achieved a 44% YoY increase in Q3 2024, surpassing 2 million active users. Find out what positions HIMS as a key ...

Hims & Hers Health Inc. shares surged 24% to close at fresh record after Hunterbrook Media said the company is poised to be a ...

Finding the right treatment for erectile dysfunction (ED) can feel overwhelming with so many options out there! Rugiet, ...

On Wednesday, Hims & Hers Health Inc (HIMS) stock saw a decline, ending the day at $30.34 which represents a decrease of $-0.34 or -1.11% from the prior close of $30.68. The stock opened at $31.49 and ...

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions ...

Hims & Hers' financials are robust, with strong and accelerating revenue growth, growing free cash flow, manageable SBC, and ...

Hims & Hers (HIMS) is up 14.0%, or $4.29 to $34.97.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium ...

The tech giant said it would offer upfront, monthly pricing for customers seeking consultations and medications for five ...

The stock price of Hims & Hers Health (NYSE: HIMS), a telehealth platform, has risen a solid 14% in a week. Much of this move came after the U.S. FDA asked for more time to confirm the shortage of ...

Shares of Hims & Hers (NYSE: HIMS) jumped as much as 23% in trading on Monday after President Trump announced his new Food and Drug Administration (FDA) chief, who happens to have ties to a ...

Hims is one of the many platforms that offer telehealth online from licensed providers, with services spanning from skincare and hair loss to anxiety and erectile dysfunction. This review examines ...